Total Synthesis of the Hydroxyketone Kurasoin A
Using Asymmetric Phase-Transfer Alkylation
Merritt B. Andrus,* Erik J. Hicken, Jeffrey C. Stephens, and
D. Karl Bedke
FIGURE 1. Hydroxyketone farnesyltransferase inhibitors kurasoin A
and B.
Department of Chemistry and Biochemistry, Brigham Young
UniVersity, C100 BNSN, ProVo, Utah 84602-5700
thesis of kurasoin A together with important findings concerning
the transformation of nonracemic ester products of this type
into ketone products without isomerization and epimerization.
The modular approach is accommodated through precursor
3 with suitable protecting groups for the phenolic and hydroxyl
functionality (Scheme 1). The protecting groups P and P′ must
be easily removed without epimerization of the R-hydroxyl,
prevent tautomerization to the hydroxyketone isomer, and allow
for benzyl addition to a suitable acyl derivative 4. The
4-hydroxyphenyllactate intermediate 4 is assembled using a
phase-transfer alkylation with the protected benzyl halide 5 and
the glycolate enolate 6. This flexible route can be easily
modified, using alternative reagents for acyl addition and enolate
alkylation, to directly access analogues of kurasoin A and B.
Asymmetric, catalytic enolate alkylation with sp3-electrophiles
is a challenging transformation that has been met with only
limited success with specific substrates. Koga pioneered the use
of chiral polyamines for alkylation of cyclic silylenol ethers,6
and List has recently demonstrated that iodoaldehydes undergo
intramolecular proline-catalyzed alkylations.7 More recently,
Jacobsen has employed chromium-salen catalysts for the
alkylation of cyclic tin enolates.8
ReceiVed July 5, 2006
The total synthesis of the farnesyltransferase inhibitor
kurasoin A has been achieved using a novel asymmetric
phase-transfer-catalyzed glycolate alkylation reaction. 2,5-
Dimethoxyacetophenone 7 with cinchonidinium catalyst 9
(10 mol %) and hydroxide base with pivaloyl benzyl bromide
8 provided S-alkylation product 10 in high yield (80-99%)
and excellent enantioselectivity. Baeyer-Villiger oxidation,
Weinreb amide formation, and benzyl Grignard addition to
the TES-ether 17 gave the protected target. Lithium hydrox-
ide and peroxide generated kurasoin A ([R]D +8.4°) without
isomerization.
We previously reported the development of asymmetric PTC
glycolate alkylation of aryl ketone 7 with various electrophiles
using the cinchonidine-derived catalyst 9 of Park and Jew, which
was originally reported for glycine alkylation.5 The benzhydryl
group (DPM, diphenylmethyl) and the 2,5-dimethoxyphenyl
ketone 7 were essential for both reactivity and the selectivity
of the novel glycolate alkylation (Scheme 2). Alkylations of
this type were previously limited to the benzophenone imine-
protected glycine substrate of O’Donnell, where extended
π-delocalization allows for enolate formation and catalyst
interaction.9 In this case for glycolate alkylation, it was found
that liquid-solid PTC conditions with cesium hydroxide hydrate
Kurasoin A 1 and B 2 were isolated by Omura during a search
for protein farnesyltransferase (PFTase) inhibitors from the soil
fungus, Paecilomyces sp. (Figure 1).1 These simple compounds
hold potential for new lead development in that the aromatic
substituents can be easily modified in a modular fashion around
a central R-hydroxy ketone core.2 A combination of NMR
spectroscopy and synthesis was used to establish the absolute
stereochemistry. A seven-step asymmetric route from 4-hy-
droxyphenyl-2-ethanol (5% overall yield) to kurasoin A 1 was
used to establish the stereochemistry with a Sharpless asym-
metric epoxidation that gave a key intermediate in low yield,
25%.3 A racemic route to 1, using benzyl Grignard addition to
a Weinreb amide, was also reported.4 We recently developed
an efficient asymmetric, phase-transfer catalytic (PTC) glycolate
alkylation process for the synthesis of R-hydroxy ester products,
including a route to the diabetes drug (-)-ragaglitazar.5 We now
report the application of this new process for an efficient syn-
(5) (a) Andrus, M. B.; Hicken, E. J.; Stephens, J. S. Org. Lett. 2004, 6,
2289. (b) Andrus, M. B.; Hicken, E. J.; Stephens, J. C.; Bedke, D. K. J.
Org. Chem. 2005, 70, 9470. For auxiliary-based approaches to glycolate
alkylation, see: (c) Crimmins, M. T.; Emmitte, K. A.; Katz, J. D. Org.
Lett. 2000, 2, 2165. (d) Schmidt, B.; Wildermann, H. J. Chem. Soc., Perkin
Trans. 1 2002, 1050. (e) Chappell, M. D.; Stachel, S. J.; Lee, C. B.;
Danishefsky, S. J. Org. Lett. 2000, 2, 1633. (f) Burke, S. D.; Quinn, K. J.;
Chen, V. J. J. Org. Chem. 1998, 63, 8626.
(6) Imai, M.; Hagihara, A.; Kawasaki, H.; Manabe, K.; Koga, K. J. Am.
Chem. Soc. 1994, 116, 8829.
(1) Uchida, R.; Shiomi, K.; Inokoshi, J.; Masuma, R.; Kawakubo, T.;
Tanaka, H.; Iwai, Y.; Omura, S. J. Antibiot. 1996, 49, 932.
(2) (a) Kohl, N. E.; Wilson, F. R.; Mosser, S. D.; Giuliani, E.; DeSolms,
S. J. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 9141. (b) Kohl, N. E.; Omer,
C. A.; Conner, M. W.; Anthony, N. J.; Davide, J. P. Nat. Med. 1995, 1,
792.
(3) (a) Sunazuka, T.; Hirose, T.; Zhi-Ming, T.; Uchida, R.; Shiomi, K.;
Harigaya, Y.; Omura, S. J. Antibiot. 1997, 50, 453. (b) Hirose, T.; Sunazuka,
T.; Zhi-Ming, T.; Handa, M.; Uchida, R.; Shiomi, K.; Harigaya, Y.; Omura,
S. Heterocycles 2000, 53, 777.
(7) Vignola, N.; List, B. J. Am. Chem. Soc. 2004, 126, 450.
(8) Doyle, A.; Jacobsen, E. N. J. Am. Chem. Soc. 2005, 127, 62.
(9) (a) O’Donnell, M. J.; Bennett, W. D.; Wu, S. J. Am. Chem. Soc.
1989, 111, 2353. (b) O’Donnell, M. J.; Delgado, F.; Hostettler, C.;
Schwesinger, R. Tetrahedron Lett. 1998, 39, 8775. (c) Corey, E. J.; Xu, F.;
Noe, M. C. J. Am. Chem. Soc. 1997, 119, 12414. (d) Lygo, B.; Wainwright,
P. G. Tetrahedron Lett. 1997, 38, 8595. (e) Ooi, T.; Kameda, K.; Maruoka,
K. J. Am. Chem. Soc. 1999, 121, 6519. (f) Jew, S.; Yoo, M.; Jeong, B.;
Park, I. Y.; Park, H. Org. Lett. 2002, 4, 4245. (g) Park, H.; Jeong, B.; Yoo,
M.; Lee, J.; Park, M.; Lee, Y.; Kim, M.; Jew, S. Angew. Chem., Int. Ed.
2002, 41, 3036.
(4) Uchida, R.; Shiomi, K.; Sunazuka, T.; Inokoshi, J.; Nishizawa, A.;
Hirose, T.; Tanaka, H.; Iwai, Y.; Omura, S. J. Antibiot. 1996, 49, 886.
10.1021/jo061395t CCC: $33.50 © 2006 American Chemical Society
Published on Web 09/28/2006
J. Org. Chem. 2006, 71, 8651-8654
8651